Home › Ulcerative Colitis › Missouri
Ulcerative Colitis clinical trials in Missouri
16 studies for Ulcerative Colitis are looking for participants at sites in Missouri.
Cities in Missouri
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Specialists In Gastroenterology /ID# 283939, St Louis
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Oct 5, 2026 · NCT07697456Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters
- Siteman Cancer Center at West County Hospital, Creve Coeur
- University Health Truman Medical Center, Kansas City
- and 5 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT03816345Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
- BVL Research - Kansas ( Site 0292), Liberty
RecruitingPhase 3
All ages · All sexes · Updated Oct 2, 2026 · NCT06651281A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- SSM Health Medical Group, Bridgeton
- GI Associates Research, LLC, Columbia
- Mid America Gastro Intestinal Consultants, Kansas City
- and 1 more
RecruitingPhase 4
Ages 18 to 80 · All sexes · Updated Sep 30, 2026 · NCT06581328A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis
- Site US-006, St Louis
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 29, 2026 · NCT07845487A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)
- BVL Research - Kansas ( Site 1054), Liberty
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 28, 2026 · NCT07463183A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
- Washington University, St Louis
RecruitingPhase 2/3
Ages 2 to 17 · All sexes · Updated Sep 24, 2026 · NCT05076175Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Washington University School of Medicine, St Louis
RecruitingPhase 3
Ages 18 to 70 · All sexes · Updated Sep 24, 2026 · NCT06937086LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
- KAD Clinical Research, St Louis
- Specialists in Gastroenterology, St Louis
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Sep 22, 2026 · NCT07415044A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
- Washington University School of Medicine, St Louis
RecruitingPhase 3
Ages 2 to 19 · All sexes · Updated Sep 22, 2026 · NCT04844606A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
- KAD Clinical Research, St Louis
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Sep 22, 2026 · NCT07483073A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
- Mid-America Gastro-Intestinal Consultants, Kansas City
- BVL Clinical Research, Liberty
- Washington University School of Medicine, St Louis
RecruitingPhase 4
Ages 18 to 65 · All sexes · Updated Sep 21, 2026 · NCT06095128A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
- Gateway Gastroenterology - Site Number: 8400097, Chesterfield
- BVL Clinical Research - Site Number: 8400005, Liberty
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Sep 15, 2026 · NCT07185009An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
- Gateway Gastroenterology - Site Number: 8400097, Chesterfield
- BVL Clinical Research - Site Number: 8400005, Liberty
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Aug 20, 2026 · NCT07184996BOOM-IBD2 Pivotal Clinical Trial
- Gateway GI Research (Objective Health), St Louis
Recruiting
Ages 18 to 85 · All sexes · Updated Aug 6, 2026 · NCT06571669A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Bridgeton
- Mirador Therapeutics Selected Site, Kansas City
- Mirador Therapeutics Selected Site, Liberty
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Mar 12, 2026 · NCT07113522From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.